History of Milenia Biotec

Milenia has been founded by private shareholders in Bad Nauheim. The city, located in the center of Germany, is a spa primarily dedicated to health care since centuries.

Milenia QuickLine IL-6, the first kit allowing a true point-of-care measurement of IL-6, has been launched by Milenia Biotec. The kit helped neonatologists worldwide to improve the diagnosis of sepsis in preterm born infants and to create the basis to reduce unnecessary antibiotic treatments and unnecessary admissions to neonatal intensive care wards.

PicoScan has been introduced to the market and allowed the (semi-) quantitative measurements of the Milenia QuickLine IL-6.

Milenia HybriDetect, has been released and became a core product of the company. Milenia HybriDetect is a universal lateral flow strip and serves for any developer as a simple rapid test development platform.

Milenia Biotec successfully passed the first ISO audit by TÜV Rheinland and was granted a ISO certificate according to EN ISO 13485.

Milenia HybriDetect 2T has been released to the market. The product allows the detection of two analytes on the same strip and is intended to be used for duplex testing in molecular biology based methods.

The first scientific paper citing the use of Milenia HybriDetect in a molecular biology based method has been published by Piepenburg O. et al.

Milenia Biotec moves from Bad Nauheim to Gießen, a university city with 84.000 inhabitants, 45% of them are students. The university of Gießen/Marburg with its medical faculty is in the close vicinity of the company.

The POCScan instrument for the point-of-care measurement of Milenias lateral flow tests has been launched. It is the first true stand alone instrument available from Milenia Biotec. The first quantitative test available on POScan is Milenia QuickLine IL-6.

Milenias project „Detection of gun shot residues with a simple lateral flow test“ has been selected by the funding agency AiF as 1 of the 12 most innovative projects for their 2011 calender. AiF has selected the projects from more than 10.000 funded projects.

Milenia Biotec opens an own R&D group dedicated to the development of antigens and antibodies.

Milenia QuickLine HIT has been launched to the market. The test allows the exclusion of a heparin induced thrombocytopenia in patients at a suspision of a HIT on a very high level of sensitivity and specificity.

Milenia Biotec joins the Bio-DrIM consortium, a group of European universities and companies dealing with the biomarker driven personalized immunosuppression in transplant patients.

Milenia Biotec opens an own R&D group dedicated to the development of medical apps.

Milenia joins Network ProAnimalLife.

Milenia expands office floor space of the company building.

Milenia Biotec opens R&D group dedicated to the development of molecular biology based PCR tests. The first project is the development of a series of PCR-tests for the detection of beer spoilage bacteria. All tests are based on Milenia HybriDetect our universal strip development platform.

German Brewers Association grants Innovation Award to Jennifer Koob, cooperation partner of Milenia in the project „Detection of beer spoilage bacteria with a simple lateral flow test“.

GenLine tests for the detection of beer spoilage bacteria launched to the market.

Milenia GenLine Alicyclobacillus tests are launched to the market.

Milenia receives research grants for the project „VirusDetect“. The project is the contribution of Milenia to the network ProAnimalLife.

First CRISPR based paper citing the use of Milenia HybriDetect published.

GenLine Hygienemonitoring launched to the market.

Stifterverband grants innovation seal to Milenia Biotec.

Milenia Biotec launches company page on LinkedIn.

Milenia HybriDetect used in a series of papers for the detection of SARS-CoV-2.

Use of Milenia HybriDetect cited in 145 scientific papers.